WHO Urges Global Introduction of Maternal Vaccination and Antibodies for Infants' RSV Prevention

Nairobi, Kenya - The World Health Organization (WHO) has made a groundbreaking recommendation, calling on all countries to introduce maternal vaccination and/or long-acting monoclonal antibodies to prevent severe respiratory syncytial virus (RSV) disease in young infants. This move marks a significant milestone towards global scale-up of these lifesaving interventions.

According to the WHO, overcoming barriers to introduction and shortening product availability timelines remains essential to bridge the gap between need and access for low- and middle-income markets. PATH and its partners have been working diligently to develop tools and gather evidence to support informed decision-making and implementation planning for countries facing RSV-related challenges.

As the demand for these new interventions continues to grow, it is crucial that a concerted effort is made to raise awareness, address existing hurdles, and expedite product distribution. With WHO's endorsement,PATH's efforts take on added significance as they drive progress towards equitably distributing these life-saving vaccine and antibody technologies globally.